Quick Answer
Aptevo Therapeutics Inc. reported Long Term Debt of $1.46 million for the year ending 2022.
- Aptevo Therapeutics Inc. showed a decrease of -60.7% in Long Term Debt from 2021 to 2022.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2024.
- XBRL data for this metric is available from 2016 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $18.11 million | Q1 2017: $18.44 million | Q2 2017: $18.75 million | Q3 2017: $17.48 million | Q1 2018: $13.98 million | Q2 2018: $15.40 million | Q3 2018: $19.14 million | Q1 2019: $19.42 million | Q2 2019: $19.56 million | Q3 2022: $1.91 million.
- Over the full 5 years of available data (2016 to 2022), Aptevo Therapeutics Inc.'s Long Term Debt has declined by 92.1%.
- Historical annual values: Fiscal year 2022: $1.46 million | Fiscal year 2021: $3.71 million | Fiscal year 2018: $19.28 million | Fiscal year 2017: $15.73 million | Fiscal year 2016: $18.38 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: